In the latest trading session, 0.69 million shares of the Esperion Therapeutics Inc. (NASDAQ:ESPR) were traded, and its beta was 0.99. Most recently the company’s share price was $1.85, and it changed around -$0.06 or -3.14% from the last close, which brings the market valuation of the company to $363.01M. ESPR currently trades at a discount to its 52-week high of $3.40, offering almost -83.78% off that amount. The share price’s 52-week low was $0.70, which indicates that the current value has risen by an impressive 62.16% since then. We note from Esperion Therapeutics Inc.’s average daily trading volume that its 10-day average is 2.92 million shares, with the 3-month average coming to 6.01 million.
Esperion Therapeutics Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.71. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ESPR as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Esperion Therapeutics Inc. is expected to report earnings per share of -0.17 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Instantly ESPR has showed a red trend with a performance of -3.14% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.9100 on recent trading dayincreased the stock’s daily price by 3.14%. The company’s shares are currently down -38.13% year-to-date, but still up 8.82% over the last five days. On the other hand, Esperion Therapeutics Inc. (NASDAQ:ESPR) is -6.09% down in the 30-day period. We can see from the shorts that 40.44 million shares have been sold at a short interest cover period of 9.25 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 88.44% from its current value. Analyst projections state that ESPR is forecast to be at a low of $12 and a high of $20.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Esperion Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -10.63 percent over the past six months and at a 98.03% annual growth rate that is well above the industry average of 20.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 54.10% in revenue this quarter, and will report an increase of 90.00% in the next quarter. The year-over-year growth rate is expected to be 199.40%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 53.52M in revenue for the current quarter. 5 analysts expect Esperion Therapeutics Inc. to make 62.82M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 94.80%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 23.09%. Esperion Therapeutics Inc. earnings are expected to increase by 87.85% in 2024, but the outlook is positive 16.90% per year for the next five years.
ESPR Dividends
Esperion Therapeutics Inc.’s next quarterly earnings report is expected to be released on 2024-Nov-05.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.50% of Esperion Therapeutics Inc. shares, and 70.52% of them are in the hands of institutional investors. The stock currently has a share float of 70.88%. Esperion Therapeutics Inc. stock is held by 209.0 institutions, with WASATCH ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 9.9628% of the shares, which is about 16.86 million shares worth $37.44 million.
BLACKROCK INC., with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jun 30, 2024. The former held 6.68 shares worth $12.35 million, making up 3.40% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 5.67 shares worth around $10.49 million, which represents about 2.89% of the total shares outstanding.
